MedTrace Logo

Safety and Immunogenicity of the Candidate Vaccine MVA-MERS-S_DF-1 Against MERS

NCT04119440 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2025-04-24

No results posted yet for this study

Summary

The study will be a two center, randomized, double blind, placebo controlled study of the MVA MERS S\_DF-1 candidate delivered by i.m. injection. To evaluate the MERS-S-specific antibody responses and safety profile induced by the two dosage levels of MVA-MERS-S\_DF-1 the data will be compared to a placebo control group.

Conditions

  • MERS (Middle East Respiratory Syndrome)

Interventions

BIOLOGICAL

MVA-MERS-S_DF1 - Low Dose

Administrations of the low dose via the intramuscular route

BIOLOGICAL

MVA-MERS-S_DF1 - High Dose

Administrations of the high dose via the intramuscular route

OTHER

Placebo

Administrations of placebo via the intramuscular route

Sponsors & Collaborators

  • Coalition for Epidemic Preparedness Innovations

    collaborator OTHER

  • IDT Biologika Dessau.Rossau

    collaborator UNKNOWN

  • German Center for Infection Research

    collaborator OTHER

  • CR2O

    collaborator UNKNOWN

  • Erasmus Medical Center

    collaborator OTHER

  • Monipol Deutschland GmbH

    collaborator UNKNOWN

  • Universitätsklinikum Hamburg-Eppendorf

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-16
Primary Completion
2022-11-28
Completion
2024-11-06

Countries

  • Germany
  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04119440 on ClinicalTrials.gov